Tags : Hong Kong

BioNTech and Fosun Pharma to Supply ~10M Doses of COVID-19

Shots: BioNTech and Fosun collaborated to supply 10M doses of their BNT162 mRNA-based vaccine candidate against COVID-19 to Hong Kong SAR and Macao SAR, once approved Fosun Pharma has signed the Letter of Intent with Jacobson for contemplated distribution of 10M doses of a vaccine targeting COVID-19 in the Chinese market On Mar 13, 2020, […]Read More

Mundipharma Collaborates with Samsung Bioepis to Commercialize Multiple Biosimilar Candidates

Shots: Mundipharma to get exclusive commercialization rights for Samsung Bioepis’ first-wave biosimilar candidates in Taiwan and Hong Kong while Samsung Bioepis will remain MAH, responsible for the development, regulatory and manufacturing activities of therapies The biosimilar candidates include SB5 (adalimumab), SB4 (etanercept), SB3 (trastuzumab), and SB8 (bevacizumab) targeting immunology & oncology The collaboration combines Samsung […]Read More

Mithra Signs a License Agreement with Alvogen for its Estelle

Shots: Mithra to get up front, sales milestones, royalties and recurring revenues based on Minimal Annual Quantities (MAQ) and will manufacture Estelle at its Contract Development and Manufacturing Organization facility in Belgium. Alvogen to get exclusive commercialization rights for Mithra’s Estelle in Hong Kong and Taiwan The agreement follows its previous licensing deals for Estelle […]Read More

Apple Launches its Watch Series 4 Enabled with ECG App

Shots: The ECG app on Apple Watch Series 4 is evaluated in 600 patients resulted in 98.3% sensitivity in classifying AFib, 99.6% specificity in classifying sinus rhythm, 87.8% of recordings classified by the ECG app The irregular rhythm notification function was assessed in the Apple Heart study enrolled with 400,000 candidates and demonstrated 0.5% irregular […]Read More